



ASX ANNOUNCEMENT

2 June 2026

Vitrafy enters a partnership with Vitalant Innovation Center

Vitrafy Life Sciences Ltd (“**Vitrafy**” or “**the Company**”) (ASX: **VFY**) today announces a partnership with Vitalant Innovation Center (“**Vitalant**”) to configure Vitrafy’s next-generation cryopreservation ecosystem to solve the looming crisis for red blood cell preservation. The partnership aims to address a pivotal industry transition: as existing frozen red blood cell (“**RBC**”) technologies reach the end of its operational life – with no replacement presently available.

Highlights

- Vitrafy and Vitalant to partner to configure Vitrafy’s cryopreservation ecosystem to meet the urgent market need within cryopreserved red blood cells.
- Vitalant is the second-largest blood network in the USA, representing approximately 10% of the collection market with 125 sites and serving over 900 hospitals.
- Partnership addressing an urgent market need created by the discontinuation of legacy technologies used to cryopreserve red blood cells, for which no replacement currently exists.
- Vitrafy expects this opportunity to expand to other blood products, with the aim that the Vitrafy ecosystem becomes the successor to existing end-of-life legacy technologies across the U.S. blood network.
- Broad market engagement and support across civilian blood network participants in response to the urgent RBC market need.

Overview

Vitrafy today announces that it has entered a partnership with Vitalant to configure its next generation cryopreservation ecosystem to specifically address the critical problem facing the industry relating to the end-of-life of legacy technology in the cryopreservation of red blood cells.

Vitrafy intends this partnership to address the emerging threat posed to existing red blood cell stockpiles and market-wide red blood cell cryopreservation workflows by the announcement that critical legacy technology and products will be discontinued from 2027. These products include a glycerol based cryoprotectant and a cell washing technology – two critical steps within current red blood cell cryopreservation workflow.

The end-of-life of the legacy glycerol-based freezing technology threatens the ability to keep red blood cells in cryopreserved, long-term stockpiles. Without successor technology, the blood system risks losing the stockpiling and preservation capability that trauma response depends on, particularly for rare blood types and for keeping supply ready in emergencies, mass-casualty events, and remote or military settings.

Under the partnership, Vitrafy and Vitalant will contribute resources to deliver a market wide solution to the emerging threat to the industry’s operating workflows and stockpiles relating to cryopreserved red blood cells.



With the recent announcement of the Company's US Army in-vitro platelets results, Vitrafy believes this opportunity could expand to additional blood-based products, such as platelets.

Vitrafy will initially place two cryopreservation freezing units into the Vitalant Innovation Center in Denver, Colorado. The placement will not generate revenue, but the Company expects the partnership to support broader market and government engagement toward a unified response.

About Vitalant

Vitalant is one of the United States' largest non-profit blood and biotherapies healthcare organisations, providing hospitals and patients a safe blood supply. Vitalant has a network of around 125 donation centers¹ across the U.S. and host approximately 60,000 blood drives annually. Vitalant provides blood and special services to patients in around 900 hospitals across the U.S.

Collecting approximately 10% of U.S. market blood supply annually², millions of patients depend on blood donations from the Vitalant Blood Network.

Outlook

Upon finalisation of the partnership Managing Director and CEO, **Brent Owens**, commented:

"We are really excited to partner with Vitalant to actively address an issue of national significance with one of the leading blood market participants in the USA.

The recognition of Vitrafy's cryopreservation ecosystem as the next generation solution to this crisis reinforces our belief that we are securing meaningful market traction and creating a pathway to significant commercial scale.

We see this partnership as the first of several potential civilian blood opportunities that have stemmed from the successful results in the U.S Army platelets study."

- ENDS -

¹ Vitalant currently operated 115 sites but is in the process of acquiring San Diego Blood Bank which operates a further 10 collection sites. The merger between Vitalant and San Diego Blood Bank is expected to close mid-2026: <https://sandiegobloodbank.org/san-diego-blood-bank-and-vitalant-announce-strategic-merger-to-enhance-community-blood-services/>

² https://www.vitalant.org/getattachment/0abd13fc-7d38-4694-b805-d36e0bd298f2/2024-community-impact-report_digital.pdf?lang=en-US page



This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Tim Sharpe
Vice President of Strategy & Corporate Development
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardion cryopreservation freezing unit, and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.